Gut dysbiosis seems to be very prevalent in people with PD and many other diseases or health issues and potentially contributes to the disease process based on available studies.
In this 2021 study they showed through fecal DNA of 107 PwP that levodopa and especially Levodopa/Carbidopa Intestinal Gel (LCIG) are associated with an inflammatory microbiome.
pubmed.ncbi.nlm.nih.gov/331...
Here is what the study concluded :
>>> ' Our results suggest that LD, and mostly LCIG, might significantly influence the microbiota composition and host/bacteria metabolism, acting as stressors in precipitating a specific inflammatory intestinal microenvironment, potentially related to the PD state and progression. ' <<<
Here are two other relevant quotes from the study :
>>> ' The LD group and LCIG group were associated with a metabolic profile linked to gut inflammation. ' <<<
>>> Compared to the Naïve group, the univariate analysis showed a reduction of Blautia and Lachnospirae in the Levodopa group. <<<
This second quote is important because Blautia and Lachnospirae are bacteria that are known to produce health promoting Short Chain Fatty Acids (SCFAs) in the gut and in studies it has been shown that PwP are low in at least the three predominant SCFAs, Acetate, Propionate and Butyrate.
Given this information, it seems like a reasonable measure to take steps to increase SCFA production as a potential means to offset this deficit associated with Levodopa use as well Levodopa Carbidopa Intestinal Gel which appears to be significantly worse than LD in this respect of gut inflammation and dysbiosis.
Art